What the K2 era actually failed at — the scheduling regime that selected for the more dangerous compounds, documented turn by turn in the Federal Register, and the distribution layer that could not handle what it was given — what the published surveys find in converted cannabinoid products, how to recognise synthetic-cannabinoid toxicity against cannabis overconsumption, and the buyer and vendor instrument that separates a tested market from the failure mode.
4 pages · 56 citations (5 without a resolved identifier, marked on the page) · updated 2026-09-27
What this section is, and what it is not
Education and harm reduction. Not medical, legal or financial advice. Every factual claim carries a source; contested and single-source claims are marked as such on the page.
The boundary. This section teaches separation, purification, formulation, dosing arithmetic and analytical chemistry with real parameters, because withholding that detail from someone who will proceed anyway is the harm this library exists to prevent. It does not publish preparative routes for converting one cannabinoid into a more intoxicating one; those are described structurally and cited to the literature, without procedures.
Pages
The documented mechanism, in the right order, and it has two halves. Scheduling was the selection pressure that chose the compound — the Federal Register records the market being driven from the JWH naphthoylindoles up to the indazole carboxamides at every enforcement step, not out of existence. And the distribution layer could not handle what it was given: bulk powder sprayed onto inert plant material by distributors with no balance, no dose calculation and no homogeneity control, with analytical identification permanently behind the analogue turnover. Layer three did the killing mechanically; the regime is what put a full agonist in layer three's hands instead of a partial one. The hazard was consuming an unidentified compound of unknown pharmacology at an unknown and non-uniform dose. It was not a knowledge gap about how to make them.
8 sections · safety
The live hemp-industry issue, stated as what the published product analyses actually report: residual acid catalysts and reaction solvents, unreacted starting material, multiple unidentified isomers and side-products showing up as unassigned chromatographic peaks, olivetol- and resorcinol-related impurities, catalyst metals that a standard four-metal panel does not look for, and label potency that does not match assay in both directions. An unassigned peak is an unidentified compound being consumed.
5 sections · safety
Cannabis overconsumption and synthetic full-agonist toxicity set side by side, because they are not the same event and do not call for the same response. Reassurance and a quiet room, which is usually right for cannabis, is not sufficient for the second. Includes the emergency thresholds, the naloxone question answered honestly, and the poison-centre facts — the Poison Help line is 1-800-222-1222, it is free and confidential, and calling it is not calling the police.
7 sections · safety
A working two-column instrument: what to demand as a buyer, what to provide as a vendor, and the red flags in one list. It closes with the argument the industry should be making — testing, labelling and traceability are the difference between this market and the K2 era, which makes them the industry's actual product rather than its compliance overhead.
4 sections · tool